Posted on 05 October 2012
Tags: dealtalk, pharma news, pharma partnering
“We’re entering unchartered territory. Not only will we identify and test treatment solutions that no one has explored before; we will also explore new therapeutic areas for LEO Pharma. By working at the forefront of drug discovery and development, LEO Pharma can go that extra mile to meet patient needs. We are excited about the possibilities ahead.”
The scope of the scientific collaboration strategy covers skin conditions in which LEO Pharma is already active, such as psoriasis, atopic dermatitis and actinic keratosis, as well as new therapeutic areas for LEO Pharma.
For further deal information visit Current Agreements (subscription required)
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
Report: Dermatology Partnering Terms and Agreements
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Click here to cancel reply.
Email (will not be published) (required)
Your website (optional)
Home | Reports | Services | Insight | News | Events | Scorecard | About us | Terms & conditions | Subscribe | Contact us
© 2013 Wildwood Ventures Ltd.